

Actelion Pharmaceuticals Ltd

[View the current Actelion Pharmaceuticals Ltd Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/17823-Actelion+Pharmaceuticals+Ltd.html)

(<http://www.bioportfolio.com/bi corporate/17823-Actelion+Pharmaceuticals+Ltd.html>)

Contact Details:

Hegenheimerweg 91

Allschwil

Allschwil

4123

Switzerland

Tel: 41 61 565 65 65

Fax: 41 61 565 65 00

Email: info@dmkzwo.de

Actelion aims to discover or in-license and develop a steady stream of new products as revenue sources, based on first-in class small molecule compounds. In doing so, Actelion is focussing on innovative treatments for high-unmet medical needs, where Actelion's new drugs can bring therapeutic advantage to patients and economic benefit for the community at large. Pursue comprehensive life cycle and label expansion anagement Actelion aims to develop products to their maximum potential by implementing comprehensive strategies of line extensions and new indications. For example, since gaining approval of Tracleer® in 2001, Actelion has continued to invest in further clinical trials to expand its use into new indications

Recent Publications by Actelion Pharmaceuticals Ltd:



- [New classes of potent and bioavailable human renin inhibitors.](#)
*New classes of de novo designed renin inhibitors are reported. Some of...*27th October, 2009
Drug Discovery and Preclinical Research, Actelion Pharmaceuticals Ltd,- Bioorg Med Chem Lett. 2009 Dec 1;19(23):6762-5. Epub 2009 Oct 1. ([DOI Direct Link](#))
- [Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.](#)
*AIMS: To investigate the effects of palosuran, a nonpeptidic, potent and...*22nd October, 2009
Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, CH-4123- Br J Clin Pharmacol. 2009 Oct;68(4):502-10. ([DOI Direct Link](#))
- [Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects.](#)
*Palosuran is a new potent and specific antagonist of the human urotensin...*25th July, 2009
Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd,- J Clin Pharmacol. 2009 Oct;49(10):1168-75. Epub 2009 Jul 22. ([DOI Direct Link](#))

- [Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.](#)
*Starting from known piperidine renin inhibitors, a new series of...*15th July, 2009
Drug Discovery and Preclinical Research, Actelion Pharmaceuticals Ltd.,- J Med Chem. 2009 Jun 25;52(12):3689-702. ([DOI Direct Link](#))
- [Biomedical application of orexin/hypocretin receptor ligands in neuroscience.](#)
*This study investigates the pharmacokinetics, pharmacodynamics, and safety...*10th July, 2009
Drug Discovery and Preclinical Research & Development, Actelion- J Med Chem. 2009 Feb 26;52(4):891-903. ([DOI Direct Link](#))
- [Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan.](#)
*This study investigates the pharmacokinetics, pharmacodynamics, and safety...*26th June, 2009
Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology,- J Clin Pharmacol. 2009 Apr;49(4):455-64. ([DOI Direct Link](#))
- [bFGF induces S1P1 receptor expression and functionality in human pulmonary artery smooth muscle cells.](#)
*Sphingosine-1-phosphate (S1P), acting through five closely related...*13th January, 2009
Actelion Pharmaceuticals Ltd., Hegenheimerweg 91, CH-4123 Allschwil,- J Cell Biochem. 2008 Nov 1;105(4):1139-45. ([DOI Direct Link](#))
- [Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.](#)
*Macitentan, also called Actelion-1 or ACT-064992...*6th January, 2009
Drug Discovery Department, Actelion Pharmaceuticals Ltd., Allschwil,- J Pharmacol Exp Ther. 2008 Dec;327(3):736-45. Epub 2008 Sep 9. ([DOI Direct Link](#))
- [Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.](#)
*BACKGROUND AND OBJECTIVE: Bosentan, an oral, dual endothelin receptor...*17th December, 2008
Actelion Pharmaceuticals Australia Pty Ltd, Frenchs Forest, NSW,- Respiriology. 2008 Sep;13(5):674-82. ([DOI Direct Link](#))
- [Distribution of neuromedin U binding sites in the rat CNS revealed by in vitro receptor autoradiography.](#)
*Neuromedin U (NMU), a neuropeptide implicated in feeding, inflammation,...*22nd October, 2008
Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil,- Neuropeptides. 2008 Aug;42(4):377-86. Epub 2008 Jun 10. ([DOI Direct Link](#))
- [N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonists.](#)
*A series of dual OX(1)R/OX(2)R orexin antagonists was prepared based on a...*11th October, 2008
Drug Discovery Chemistry and Biochemistry, Actelion Pharmaceuticals Ltd,- Bioorg Med Chem Lett. 2008 Nov 1;18(21):5729-33. Epub 2008 Sep 26. ([DOI Direct Link](#))
- [Adaptation of the Cambridge Pulmonary Hypertension Outcome Review \(CAMPHOR\) into French-Canadian and English-Canadian.](#)
*BACKGROUND: The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)...*2nd July, 2008
Actelion Pharmaceuticals Canada Inc, Laval, Canada.- Can Respir J. 2008 Mar;15(2):77-83.
- [Over-expression and purification of active serine proteases and their variants from Escherichia coli inclusion bodies.](#)
*This unit describes the over-expression and purification of active serine...*28th May, 2008
Actelion Pharmaceuticals Ltd., Allschwil, Switzerland.- Curr Protoc Protein Sci. 2002 May;Chapter 21:Unit 21.11. ([DOI Direct Link](#))
- [Mechanisms of ET-1-induced endothelial dysfunction.](#)
*There is now increasing evidence that endothelial dysfunction is an early...*28th February, 2008
Actelion Pharmaceuticals Ltd., CH-4123 Allschwil, Switzerland.- J Cardiovasc Pharmacol. 2007 Dec;50(6):621-8. ([DOI Direct Link](#))
- [Preclinical safety evaluation of Gd-EOB-DTPA \(Primovist\).](#)
*OBJECTIVES: Gadoteric acid [gadolinium-ethoxybenzyl-diethylenetriamine...*26th February, 2008
Actelion Pharmaceuticals Ltd., Allschwil, Switzerland.- Invest Radiol. 2007 Dec;42(12):830-41. ([DOI Direct Link](#))

Press Releases on Actelion Pharmaceuticals Ltd:

<p>"As an Industry, We've Been too Focused on Regulatory Approval," Says Solvay Pharmaceuticals Eric Rambeaux at the Pharma Marketing Summit.</p>	<p>26th November, 2009</p>		<p>LONDON, November 26 /PRNewswire/ -- Rambeaux joined a host of other industry leaders at eyeorpharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes</p>
<p>Onyx Pharmaceuticals Announces December 2009 Investor Events</p>	<p>25th November, 2009</p>	<p>Onyx Pharmaceuticals, Inc.</p>	<p>EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7, SAN DIEGO, Nov. 25</p>
<p>Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference</p>	<p>25th November, 2009</p>	<p>Ardea Biosciences, Inc.</p>	<p>/PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper</p>
<p>iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering</p>	<p>25th November, 2009</p>		<p>DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals's service division and Pyxis Discovery announced today that they have signed a collaborative agreement</p>
<p>Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective</p>	<p>25th November, 2009</p>	<p>Reportlinker</p>	<p>NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective http://www</p>

BioNews Results for Actelion Pharmaceuticals Ltd



- [New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular](#)

Complications

PR Newswire: Nov 23 2009 12:37AM Matching: actelion pharmaceuticals

- [New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications](#)

Bionity.com: Nov 21 2009 5:27AM Matching: actelion pharmaceuticals

- [New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications](#)

PharmiWeb: Nov 19 2009 1:40AM Matching: actelion pharmaceuticals

- [New Consortium Paves The Way For Improved Treatment Of Hypertension And Associated Vascular Complications](#)

Medical News Today: Nov 18 2009 9:31PM Matching: actelion pharmaceuticals

- [Medical News: New Consortium Paves The Way For Improved Treatment Of Hypertension And Associated Vascular Complications](#)

BioFind: Nov 18 2009 3:02PM Matching: actelion pharmaceuticals

- [Merck to strengthen work for cardio health](#)

Cardiovascular Business: Nov 18 2009 6:07AM Matching: actelion pharmaceuticals

- [New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications](#)

KOTA Territory News: Nov 17 2009 1:56PM Matching: actelion pharmaceuticals

- [New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications](#)

Individual.com: Nov 17 2009 9:51AM Matching: actelion pharmaceuticals

- [New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications](#)

TickerTech.com: Nov 17 2009 8:43AM Matching: actelion pharmaceuticals

- [Actelion Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report released](#)

PR inside: Nov 16 2009 7:19AM Matching: actelion pharmaceuticals

- [Acute Hemodynamic Effects of Single-Dose Sildenafil When Added to Established Bosentan Therapy in Patients Wit](#)

Journal of Clinical Pharmacology: Oct 21 2009 8:54PM Matching: actelion pharmaceuticals

- [Actelion Pharmaceuticals Ltd : Actelion gibt Finanzergebnis](#)

Investigate: Oct 20 2009 5:29AM Matching: actelion pharmaceuticals

- [Actelion Pharmaceuticals Ltd : Actelion announces 9-month](#)

Investigate: Oct 20 2009 5:28AM Matching: actelion pharmaceuticals

- [Pulmonary Arterial Hypertension: Baseline Characteristics From the REVEAL Registry](#)

CHEST: Oct 19 2009 10:15PM Matching: actelion pharmaceuticals

- [Actelion Pharmaceuticals Ltd \(CH\) - Actelion to discuss 9-month financial results 2009](#)

Pharma Live: Oct 15 2009 8:39PM Matching: actelion pharmaceuticals

Actelion Pharmaceuticals Ltd Patents:



- 7605269- [Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists](#)
- 7238685- [Benzo-fused heterocycles as endothelin antagonists](#)
- 7192950- [Benzazepines and related heterocyclic derivatives which are useful as orexin receptor](#)

antagonists

- 7094781- [Sulfamides and their use as endothelin receptor antagonists](#)
- 7091201- [Arylalkane-sulfonamides having endothelin-antagonist activity](#)
- 7067549- [Pyrrolidone carboxamides](#)
- 6951856- [Arylethene-sulfonamides](#)
- 6815451- [1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists](#)
- 6703392- [1,2,3,4-tetrahydroisoquinoline derivatives](#)
- 7279578- [Sulfonylamino-acetic acid derivatives](#)
- 7285549- [Sulfamides and their use as endothelin receptor antagonists](#)
- 7323465- [Alkansulfonamides as endothelin antagonists](#)
- 7544691- [Guanidine derivatives](#)
- 7538109- [Quinoxalin-3-one derivatives as orexin receptor antagonists](#)
- 7452896- [Pyrimidine-sulfamides and their use as endothelian receptor antagonist](#)
- 7435828- [Thiazolidin-4-one derivatives](#)
- 7435815- [Sulfonylamino-acetic acid derivatives](#)
- 7427613- [7-aryl-3,9-diazabicyclo\(3.3.1\)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases](#)
- 7375227- [Quinoline derivatives](#)
- 7348000- [Therapeutic compositions and methods of treating glycolipid storage related disorders](#)
- 6316453- [Aqueous pharmaceutical composition](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

